Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8913616 | 0.76 | — | — | |
| SCHEMBL16949943 | 0.63 | — | — | |
| SCHEMBL16949891 | 0.63 | — | — | |
| SCHEMBL16949913 | 0.63 | HTT (0.35) | — | |
| SCHEMBL6987840 | 0.63 | — | — | |
| SCHEMBL561465 | 0.63 | — | — | |
| SCHEMBL15386176 | 0.57 | CDC25B (0.41) | — | |
| SCHEMBL1815177 | 0.57 | — | — | |
| SCHEMBL15326918 | 0.57 | — | — | |
| SCHEMBL7093159 | 0.57 | CYP11B1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212338-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2002-06-12 | — | — | EP | claimed |
| WO-2000061594-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-10-19 | — | — | WO | claimed |
| WO-2024086713-A1 | FN3 DOMAIN-SIRNA CONJUGATES AND USES THEREOF | Aro Biotherapeutics Company (US) | 2024-04-25 | — | — | WO | disclosed |
| US-10253360-B2 | BNA clamp method | BNA INC. (JP) | 2019-04-09 | — | — | US | disclosed |
| EP-2902499-B1 | BNA CLAMP METHOD | BNA INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-2902499-A9 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150240299-A1 | BNA CLAMP METHOD | BNA INC. (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2902499-A1 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-08-05 | — | — | EP | disclosed |
| EP-1490015-B1 | NOVEL 2-AMINO-9-((2-HYDROXYMETHYL) CYCLOPROPYLIDENEMETHYL) PURINES AS ANTIVIRAL AGENTS | UNIV WAYNE STATE (US) | 2009-09-23 | — | — | EP | disclosed |
| EP-1212338-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2000061594-A2 | NUCLEOSIDE DERIVATIVES WITH PHOTO-UNSTABLE PROTECTIVE GROUPS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253360-B2 | BNA clamp method | SLC28A1, SLC28A2, NAAA | HSP90AA1 1763/4885 |
| US-20150240299-A1 | BNA CLAMP METHOD | SLC28A1, SLC28A2, NAAA | HSP90AA1 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.